Trials / Terminated
TerminatedNCT00733031
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6918 | liquid suspension, daily, oral dose |
| DRUG | gemcitabine | intravenous, doses are on an intermittent schedule |
| DRUG | pemetrexed | intravenous, dose administered every 21-days |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-08-12
- Last updated
- 2010-12-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00733031. Inclusion in this directory is not an endorsement.